# XOMA earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/XOMA) · [Earnings tab](https://www.lopjlb.com/stock/XOMA?tab=earnings) Updated: 2026-08-12T05:23:19 Quarters analyzed: 8 ## Cross-quarter narrative Across the 2014‑2025 earnings calls XOMA moved from a high‑risk ophthalmology program to a lean, licensing‑focused endocrine and royalty business. Early calls highlighted slow enrollment and financial strain around the gevokizumab EYEGUARD trials, with multiple at‑risk milestones and a twelve‑month cash runway. By mid‑2015 the company cut R&D spend, terminated EYEGUARD, and redirected resources to XOMA‑358, XOMA‑129 and XOMA‑213 while securing non‑dilutive funding. Subsequent quarters emphasized cost reductions, asset sales and a shift to partner‑funded models, stabilising the balance sheet and achieving cash‑flow positivity by 2016. The later period (2025) shows a mature royalty engine with strong cash generation, disciplined capital allocation, and a portfolio of partnered assets, though it faces new clinical setbacks (Rezolute and Gossamer failures) and litigation exposure. Overall, the narrative reflects a transition from trial‑centric uncertainty to a streamlined, licensing‑driven operation with improved financial health but lingering execution risks in remaining pipelines. ## Latest CallCard · Q4 XOMA Royalty posted strong 2025 growth, added 22 assets, achieved positive cash flow and share buybacks, while navigating clinical setbacks, litigation and upcoming 2026 milestones. **Guidance:** maintained — Management expressed optimism but did not provide specific forward guidance, noting strong growth prospects. **Tone:** mgmt 0.7 · Q&A pressure 0.4 · divergence 0.3 Prepared remarks highlighted an inflection point where royalty cash flow will cover operating costs and emphasized diversified portfolio and positive cash flow. ### Demand visibility Moderate visibility with several 2026 catalysts across the portfolio. Upcoming catalysts include Rezolute Phase III results H2 2026, volixibat VISTAS study Q2 2026, REC‑4881 FDA alignment H1 2026, and continued rollout of OJEMDA and MIPLYFFA. ### Margins / costs Lean cost structure with modest G&A rise and litigation expense, offset by strong cash receipts. Full‑year G&A $36M (up $1.5M), $1.1M litigation expense, $13M interest expense offset by $3.5M investment income; total receipts $50.5M. ### Capital allocation Disciplined allocation: $25M for acquisitions, $16M buybacks, strong cash and loan reduction. Deployed ~$25M to acquire royalty/milestone rights, repurchased ~648,000 shares for $16M, ended 2025 with $83M cash and reduced Blue Owl loan to $112.5M. ### Milestones - **OJEMDA** [on_track]: EU CHMP positive opinion Feb 26 2026 and Japan submission triggered $2M milestone. - **MIPLYFFA** [on_track]: Approved 2024, generating growing royalties and milestones. - **Rezolute Phase III (congenital hyperinsulinism)** [at_risk]: Failed primary endpoint; analysis ongoing, FDA meeting planned H1 2026. - **Gossamer seralutinib** [at_risk]: Failed primary endpoint but subgroup showed benefit; FDA discussion pending. - **Volixibat VISTAS study** [on_track]: Results expected in Q2 2026 for PSC/Biliary cholangitis. - **REC‑4881** [on_track]: FDA alignment meeting planned in H1 2026 for FAP study. - **Generation Bio ctLNP platform** [new]: Out‑licensing discussions underway; non‑human primate data shows liver‑bypass delivery. - **Generation Bio iqDNA platform** [new]: Early‑stage DNA delivery tech; seeking funding and out‑licensing partners. ### Fears / risks - **Clinical setbacks**: Recent Phase III failures for Rezolute and Gossamer could postpone expected royalty growth. - **Litigation risk**: Outcome of TREMFYA breach claim is uncertain and could affect future royalty streams. - **Revenue concentration**: Royalties heavily weighted to VABYSMO, OJEMDA and MIPLYFFA; any slowdown would impact cash flow. - **Debt obligations**: Blue Owl loan repayment depends on continued VABYSMO receipts; refinancing risk exists. - **Market adoption risk**: New product launches may not achieve projected sales, affecting royalty receipts. - **Out‑licensing execution**: Monetization of Generation Bio platforms is uncertain and may not generate expected milestones. - **Regulatory risk**: Pending approvals for volixibat, REC‑4881 and other late‑stage assets could be delayed. - **Portfolio concentration**: Large share of assets in late‑stage or commercial stage could increase binary risk. ### Key quotes > “We are approaching the inflection point when expected cash flows from our royalty receipts alone should cover the core operating costs of the company.” > “Full year GAAP net income was $31.7 million compared to a GAAP net loss of $13.8 million in 2024.” > “We feel very confident that we have a justifiable claim.” ## Quarter one-liners - **2025 Q4:** XOMA Royalty posted strong 2025 growth, added 22 assets, achieved positive cash flow and share buybacks, while navigating clinical setbacks, litigation and upcoming 2026 milestones. - **2016 Q4:** XOMA announced a strategic shift to a licensing‑focused, low‑cost model, cut debt, raised $25 M, and aims for cash‑flow positivity while relying on future partner milestones. - **2015 Q4:** XOMA refocused on endocrine assets XOMA 358, 129 and 213, halted gevokizumab studies to save costs and fund development, with data expected in 2016 amid moderate trial and financing uncertainty. - **2015 Q3:** XOMA pivots to an endocrine focus, cutting non‑core programs, securing $50.5 M non‑dilutive funding and advancing XOMA‑358 Phase 2 trials while trimming staff to ~90. - **2015 Q2:** XOMA is refocusing on its endocrine franchise, cutting R&D spend, winding down the costly EYEGUARD studies, continuing a pyoderma gangrenosum program with go/no‑go checkpoints, and seeking licensing deals to extend its cash runway. - **2015 Q1:** XOMA is awaiting the final EYEGUARD‑B exacerbation, expects data about seven weeks later, and is preparing a pre‑BLA package while reaffirming its $60‑$65M cash guidance. - **2014 Q4:** XOMA reports declining 2014 revenue, a $60M cash burn in 2015, progress on gevokizumab EYEGUARD trials and Phase I XOMA 358, while seeking enrollment bolus and partnership for XMet programs. - **2014 Q3:** XOMA is advancing gevokizumab in Behçet's uveitis and pyoderma gangrenosum while facing slower-than-expected trial enrollments and uncertainty around EYEGUARD‑B exacerbations. ## Theme arcs - **EYEGUARD program** (resolved): Program terminated in 2015, ending enrollment and regulatory risk - **Endocrine pipeline development** (improving): Progress on XOMA‑358, 129, 213 with ongoing trials and partner support - **Licensing and partner model** (new): Shift to low‑cost, milestone‑driven licensing strategy from 2016 onward - **Financial runway management** (improving): Cost cuts, debt repayment and positive cash flow achieved by 2025 - **Royalty revenue growth** (improving): Strong 2025 royalty performance and share buybacks - **Clinical execution risk** (deteriorating): Recent Phase III failures for Rezolute and Gossamer increase uncertainty - **Litigation risk** (new): TREMFYA breach claim introduced in 2025 ## Guidance path 2014 Q3:maintained → 2014 Q4:maintained → 2015 Q1:maintained → 2015 Q2:withdrawn → 2015 Q3:maintained → 2015 Q4:maintained → 2016 Q4:vague → 2025 Q4:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/XOMA`